On May 25, at the China AI Drug Discovery Conference held in Shanghai, Dr. Jian Ma, co-founder and CEO of XtalPi, hosted the brand launch event of XtalPi Pharma under the theme of "Smart New Life, Leading the Future." XtalPi Pharma is an exclusive brand focusing on early-stage R&D of innovative drugs, powered by advanced AI technology. It boasts two distinct technology platforms: ID4Inno™ for innovative small molecule discovery and XupremAb™ for next-generation innovative large molecule discovery.
Leman Biotech had the privilege of being invited to the launch ceremony. Dr. Dudu Tong, R&D Director of Leman Biotech, took the stage and shared insights into Leman Biotech`s core technologies, pipeline progress, and how AI can drive the development of novel immunometabolism drugs. Currently, Leman Biotech's self-developed Meta10-19 injection has entered the IIT clinical study and has already completed dosing and observation on the first subject. This groundbreaking therapy achieved clinical cure by eliminating lymphoma cells from the patient's body with a remarkably low dose of metabolism-enhanced CAR-T. In addition, Leman Biotech, in collaboration with Xtalpi, has developed MetaAI-10, an AI superkines development platform. Furthermore, they have recently acquired over 5,000 immunometabolic modulators with ultra-high affinity, enhancing the continuous upgrade of the core technology Meta 10—Leman Biotech's metabolic reprogramming platform.
AI technology is rapidly advancing, bringing transformative changes to the biomedical field. Leman Biotech is actively applying this cutting-edge AI technology to develop novel CAR-T designs. Their focus is on creating immunotherapy drugs that are highly specific and have low toxicity, with the ultimate goal of benefiting cancer patients. By integrating AI technology into their research and development processes, Leman Biotech aims to make significant advancements that improve treatment outcomes in the field of cancer immunotherapy.
